Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 4Phase 1/2 3Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 1

Conditions

Sarcoma 2Pancreatic Neoplasms 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Cisplatin 111Carboplatin 111pembrolizumab 109Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × olaratumab × Clear all
NCT03086369 2022-06-28

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

Phase 1/2 Completed
184 enrolled 22 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02659020 2022-05-09

ANNOUNCE 2

Eli Lilly and Company

Phase 1/2 Completed
310 enrolled 33 charts
Sarcoma

Sarcoma

NCT01185964 2017-04-14

A Study of Olaratumab in Soft Tissue Sarcoma

Eli Lilly and Company

Phase 1/2 Completed
148 enrolled 21 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡